New York, NY, March 19, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced ...

Given these promising results and a strong scientific rationale, combined with LX-101’s novel mechanism of action and prior positive clinical experience in oncology, Lirum is planning new clinical ...

LX-101 is a clinical stage, novel, payload-bearing, targeted therapy directed to IGF-1R. LX-101 enables precise delivery of methotrexate, a drug widely used in autoimmune disease and with a ...

The Charlottetown Islanders had extra motivation on March 16, and it was all because of six young people. SUMMERSIDE, P.E.I. — It was a big Day 2 of competition at the 2025 Canadian mixed doubles ...

We have seen $6,530,283,928 of award payments to $LHX over the last year. Members of Congress have traded $LHX stock 1 times in the past 6 months. Of those trades, 1 ...

We have seen $1,426,200,654 of award payments to $MMS over the last year. $MMS insiders have traded $MMS stock on the open market 10 times in the past 6 months. Of ...